• Explore /
  • Poster
  • / A phase 1, first-in-human, open label, escalation and expansion study of ORM-5029, a highly potent GSPT1 degrader targeting HER2, in patients with HER2-expressing advanced solid tumors.

A phase 1, first-in-human, open label, escalation and expansion study of ORM-5029, a highly potent GSPT1 degrader targeting HER2, in patients with HER2-expressing advanced solid tumors.

Abstract Poster

Authors

null

Sara A. Hurvitz

Division of Hematology/Oncology, David Geffen School of Medicine at the University of California Los Angeles/Jonsson Comprehensive Cancer Center, Los Angeles, CA

Sara A. Hurvitz , Erika P. Hamilton , Alexander I. Spira , Paula R Pohlmann , Antonio Giordano , Katherine Clifton , Barry Douglas Anderson , Sujoy Dutta , Umesh Mangipudi , Shikha Saini , James Palacino , Tina Karunaratne , Dennise Greensmith , Olaf Christensen , Sharon Wilks

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

HER2-Positive

Clinical Trial Registration Number

NCT05511844

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS1114)

DOI

10.1200/JCO.2023.41.16_suppl.TPS1114

Abstract #

TPS1114

Poster Bd #

333b

Abstract Disclosures

Similar Posters

Poster

2023 ASCO Annual Meeting

FS-1502 in <em>HER2</em>-positive advanced breast cancer: Results from an open-label, phase 1 study.

FS-1502 in HER2-positive advanced breast cancer: Results from an open-label, phase 1 study.

First Author: Qiao Li

First Author: Fabrice Andre

First Author: Xichun Hu

First Author: Hideaki Bando